Last reviewed · How we verify
Heparin and Rivaroxaban — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Heparin and Rivaroxaban (Heparin and Rivaroxaban) — First Affiliated Hospital Xi'an Jiaotong University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Heparin and Rivaroxaban TARGET | Heparin and Rivaroxaban | First Affiliated Hospital Xi'an Jiaotong University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Heparin and Rivaroxaban CI watch — RSS
- Heparin and Rivaroxaban CI watch — Atom
- Heparin and Rivaroxaban CI watch — JSON
- Heparin and Rivaroxaban alone — RSS
Cite this brief
Drug Landscape (2026). Heparin and Rivaroxaban — Competitive Intelligence Brief. https://druglandscape.com/ci/heparin-and-rivaroxaban. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab